절제 기기 시장 : 디바이스 기술별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global ablation devices market size reached USD 6.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.7% during 2025-2033. The increasing prevalence of life-threatening diseases, the widespread adoption of electrophysiology to remove abnormal tissues, and the development of next-generation ablation devices with robotic navigation systems represent some of the key factors driving the market.

Ablation devices are medical instruments or tools used in various medical procedures to remove or destroy tissue, typically with the goal of treating or managing certain medical conditions. These devices work by delivering energy, such as heat, cold, or radiofrequency, to the targeted tissue, causing its removal or alteration. Ablation procedures are minimally invasive and are often preferred over traditional surgical methods because they typically result in less pain, shorter recovery times, and reduced risk of complications.

The market is experiencing growth driven by several key factors, including the increasing prevalence of life-threatening diseases such as cancer, atrial fibrillation, and chronic venous insufficiency (CVI). This rise in disease incidence underscores the demand for effective ablation procedures. Furthermore, the growing awareness among the public about the availability of minimally invasive ablation techniques is propelling market expansion. These procedures offer numerous advantages, including reduced pain, minimal scarring, decreased discomfort, and quicker patient recovery times. Additionally, the widespread adoption of electrophysiology procedures to address irregular heart rhythms and cardiac arrhythmia by removing abnormal tissues is contributing significantly to market growth. Besides, manufacturers are also responding to evolving medical needs by creating non-thermal, non-tumescent, and non-sclerosant endovenous ablation devices tailored for the effective treatment of superficial vein reflux.

Ablation Devices Market Trends/Drivers:

Increasing prevalence of life-threatening diseases

Cancer remains one of the leading causes of death worldwide, with a rising incidence in recent years. Ablation procedures, particularly in oncology, have gained prominence as minimally invasive alternatives to surgery. They are employed to destroy cancerous tissues in various organs, such as the liver, kidney, and lung. Moreover, CVI is a condition where veins in the legs fail to adequately return blood to the heart, leading to pain, swelling, and skin changes. Endovenous ablation procedures are now commonly used to treat CVI by closing off malfunctioning veins. The rising incidence of CVI, often associated with lifestyle factors and aging, has driven the demand for ablation devices designed for venous treatments.

Widespread adoption of electrophysiology

Electrophysiology is a branch of cardiology that deals with the electrical activity of the heart. It has witnessed a surge in adoption due to its effectiveness in diagnosing and treating various cardiac arrhythmias, including atrial fibrillation. Electrophysiology-guided ablation procedures involve precisely locating and eliminating the source of abnormal electrical signals in the heart. This approach has become the standard of care for many heart rhythm disorders, offering patients a chance for symptom relief and improved quality of life. Moreover, with healthcare professionals increasingly recognizing the benefits of electrophysiology-guided ablation, its adoption has become widespread, leading to a growing demand for related ablation devices and equipment.

Integration of next-generation ablation devices with robotic navigation systems

The advancement of technology in the field of ablation devices is a significant driving force. Next-generation ablation devices incorporate robotic navigation systems, which enhance precision, accuracy, and procedural outcomes. Robotic-assisted ablation allows for more controlled and targeted tissue ablation, reducing the risk of complications and improving patient outcomes. These robotic systems provide real-time imaging and mapping of the treatment area, enabling healthcare providers to navigate complex anatomical structures with greater confidence. As a result, the adoption of these advanced ablation devices is on the rise, particularly among healthcare facilities looking to offer state-of-the-art treatment options. The promise of improved patient safety and procedural success rates further fuels the demand for these devices.

Ablation Devices Industry Segmentation:

Breakup by Device Technology:

• Radiofrequency Devices
• Laser/Light Ablation
• Ultrasound Devices
• Cryoablation Devices
• Others

Radiofrequency devices represent the most used device technology

RF ablation has demonstrated effectiveness across a wide range of medical applications. It is used to treat conditions such as cardiac arrhythmias (e.g., atrial fibrillation), liver tumors, kidney tumors, and chronic pain management. This versatility makes RF technology a go-to choice for physicians dealing with various medical specialties. Moreover, RF ablation has a long history of safe and successful use in medical procedures. The technology has been refined over the years, and clinicians have extensive experience with its application. This track record of safety and efficacy instills confidence in both healthcare providers and patients.

Breakup by Application:

• Cancer Treatment
• Cardiovascular Disease Treatment
• Ophthalmologic Treatment
• Gynecological Treatment
• Urological Treatment
• Cosmetic Surgery
• Others

Cancer treatment holds the largest market share

Cancer is a widespread and prevalent disease that affects millions of people globally. It can occur in various organs and tissues, leading to a high demand for effective treatment options. As the incidence of cancer continues to rise due to factors like aging populations and lifestyle changes, the need for cancer treatment methods, including ablation, remains significant. Moreover, ablation techniques have proven to be versatile in the field of oncology. These procedures can be used to treat both primary tumors and metastatic lesions, making them applicable across different stages and types of cancer. Ablation can be employed in various organs, such as the liver, kidney, lung, and bone, providing clinicians with a wide range of treatment options.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Hospitals accounts for majority of market share

Ablation procedures often require specialized equipment and trained medical professionals. Hospitals are well-equipped to handle complex medical interventions and have the necessary infrastructure, including operating rooms, imaging technology, and support staff, to perform these procedures safely and effectively. This makes hospitals the natural choice for patients seeking ablation treatments. Moreover, hospitals house a wide range of medical specialties, including cardiology, oncology, gastroenterology, urology, and more. Ablation devices are used across multiple medical disciplines to treat various conditions. Hospitals can offer a comprehensive suite of ablation services, making them a one-stop destination for patients with diverse medical needs.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, particularly the United States and Canada, boasts a highly developed and advanced healthcare infrastructure. The region is home to world-renowned medical institutions, hospitals, and research centers. This advanced infrastructure provides a solid foundation for the adoption of cutting-edge medical technologies, including ablation devices. Moreover, the region has one of the highest healthcare expenditure rates in the world. This substantial investment in healthcare, both by governments and private entities, enables the procurement of state-of-the-art medical equipment, including ablation devices. It also supports research and development efforts in the healthcare sector, leading to innovation and product advancements.

Competitive Landscape:

The competitive landscape of the market is characterized by the presence of multiple players that include established brands, emerging startups, and specialty manufacturers. Presently, leading companies are allocating significant resources to research and development efforts to develop innovative and technologically advanced ablation devices. This includes the development of next-generation ablation systems with enhanced precision, safety features, and user-friendly interfaces. They are also expanding their product portfolios to offer a comprehensive range of ablation devices catering to various medical specialties and applications. This includes devices designed for cardiac ablation, oncology, pain management, gynecology, and more. Moreover, companies are expanding their reach into new geographical markets. This expansion involves obtaining regulatory approvals and certifications in different regions, establishing distribution networks, and adapting their products to meet specific regional requirements.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• AngioDynamics Inc.
• AtriCure Inc.
• Boston Scientific Corporation
• CONMED Corporation
• Elekta AB (publ)
• Johnson & Johnson
• Medtronic plc
• Olympus Corporation
• Smith & Nephew plc

Key Questions Answered in This Report

• 1.What was the size of the global ablation devices market in 2024?
• 2.What is the expected growth rate of the global ablation devices market during 2025-2033?
• 3.What are the key factors driving the global ablation devices market?
• 4.What has been the impact of COVID-19 on the global ablation devices market?
• 5.What is the breakup of the global ablation devices market based on the device technology?
• 6.What is the breakup of the global ablation devices market based on the application?
• 7.What is the breakup of the global ablation devices market based on the end user?
• 8.What are the key regions in the global ablation devices market?
• 9.Who are the key players/companies in the global ablation devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ablation Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Device Technology

• 6.1 Radiofrequency Devices
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Laser/Light Ablation
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Ultrasound Devices
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Cryoablation Devices
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Application

• 7.1 Cancer Treatment
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cardiovascular Disease Treatment
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Ophthalmologic Treatment
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Gynecological Treatment
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Urological Treatment
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Cosmetic Surgery
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgical Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AngioDynamics Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 AtriCure Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Boston Scientific Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 CONMED Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Elekta AB (publ)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Johnson & Johnson
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Medtronic plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Olympus Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Smith & Nephew plc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis